Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 801–900 of 1,689
Differential effects of the APOE genotype on brain function across the lifespan
Filippini, N., Ebmeier, K. P., MacIntosh, B. J., Trachtenberg, A. J., Frisoni, G. B., Wilcock, G. K., Beckmann, C. F., Smith, S. M., Matthews, P. M., & Mackay, C. E. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.08.009 · Cited by 196
“, 1993) and lowering the age of onset (Corder et al., 1993) in a gene-dose dependent manner.”
BackgroundToward personalized cognitive diagnostics of at-genetic-risk Alzheimer’s disease
Coughlan, G., Coutrot, A., Khondoker, M., Minihane, A.-M., Spiers, H., & Hornberger, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901600116 · Cited by 180
“Compared with the e3e3 carriers, those with the e3e4 show a threefold to fourfold increased risk for AD (44, 45).”
Tansley, S., Uttam, S., Ureña Guzmán, A., Yaqubi, M., Pacis, A., Parisien, M., Deamond, H., Wong, C., Rabau, O., Brown, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28473-8 · Cited by 177
Aluminium and the risk for alzheimer's disease
McLachlan, D. R. C. (1995) · Environmetrics · doi:10.1002/env.3170060303 · Cited by 195
Association of Bone Mineral Density with Apolipoprotein E Phenotype
Shiraki, M., Shiraki, Y., Aoki, C., Hosoi, T., Inoue, S., Kaneki, M., & Ouchi, Y. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1438 · Cited by 196
“These phenotypes were reported to be related to some involutional diseases, such as lateonset Alzheimer’s dementia((7)) and cardiovascular risk in diabetes mellitus.”
BackgroundIdentification of Novel Genes in Late-Onset Alzheimer's Disease
Pericak-Vance, M. A., Grubber, J., Bailey, L. R., Hedges, D., West, S., Santoro, L., Kemmerer, B., Hall, J. L., Saunders, A. M., Roses, A. D., et al. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00196-0 · Cited by 197
Self-citationRoßner, S. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00044-6 · Cited by 198
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease
Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Shaw, L. M., Trojanowski, J. Q., Aisen, P. S., Weiner, M., Petersen, R. C., Jack, C. R., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21953 · Cited by 195
“Age of clinical AD onset is lowered by 5 to 10 years in ε4 carriers relative to noncarriers.(1,51,52) This is supported in our data by the fact that among both AD and aMCI subjects ε4 carriers are younger than noncarriers; that is, carriers reach the same clinical disease stage at a younger age.”
The Alzheimer's Disease Sequencing Project: Study design and sample selection
Beecham, G. W., Bis, J. C., Martin, E. R., Choi, S.-H., DeStefano, A. L., van Duijn, C. M., Fornage, M., Gabriel, S. B., Koboldt, D. C., Larson, D. E., et al. (2017) · Neurology Genetics · doi:10.1212/nxg.0000000000000194 · Cited by 195
“We selected 682 additional unrelated cases from additional multiplex families that had a strong family history for LOAD.”
Self-citationCan oral infection be a risk factor for Alzheimer's disease?
Olsen, I., & Singhrao, S. K. (2015) · Journal of Oral Microbiology · doi:10.3402/jom.v7.29143 · Cited by 180
“A major risk factor for LOAD is polymorphism in the APOɛ4 allele (2).”
BackgroundUnderstanding the Amyloid Hypothesis in Alzheimer’s Disease
Paroni, G., Bisceglia, P., & Seripa, D. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180802 · Cited by 187
“2 were discovered to be the main genetic factor increasing [21–25] or decreasing [21, 26–28] the incidence of NIAD.”
Oxidative Insults Are Associated with Apolipoprotein E Genotype in Alzheimer's Disease Brain
Ramassamy, C., Averill, D., Beffert, U., Theroux, L., Lussier-Cacan, S., Cohn, J. S., Christen, Y., Schoofs, A., Davignon, J., & Poirier, J. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0273 · Cited by 195
Apolipoproteins in the brain: implications for neurological and psychiatric disorders
Elliott, D. A., Weickert, C. S., & Garner, B. (2010) · Clinical Lipidology · doi:10.2217/clp.10.37 · Cited by 194
“Inheritance of ApoE4 results in a dose-dependent increase in the risk of developing late-onset Alzheimer’s disease (AD), and is the most important genetic risk factor known for this illness, whereas ApoE2 is associated with decreased risk [64,65].”
BackgroundCholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis
Wood, W. G., Li, L., Müller, W. E., & Eckert, G. P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12637 · Cited by 194
Use of anticholinergics and the risk of cognitive impairment in an African American population
Campbell, N. L., Boustani, M. A., Lane, K. A., Gao, S., Hendrie, H., Khan, B. A., Murrell, J. R., Unverzagt, F. W., Hake, A., Smith-Gamble, V., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e7f2ab · Cited by 194
Kukull, W. A., & Ganguli, M. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70233-4 · Cited by 196
The Apolipoprotein E ϵ4 Allele and Decline in Different Cognitive Systems During a 6-Year Period
Wilson, R. S., Schneider, J. A., Barnes, L. L., Beckett, L. A., Aggarwal, N. T., Cochran, E. J., Berry-Kravis, E., Bach, J., Fox, J. H., Evans, D. A., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.7.1154 · Cited by 193
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
“Traditionally, APOE ε3/ε4 individuals and APOE ε4 homozygotes were asserted to have ~2–3 and ~9–12 times higher risk of AD than APOE ε3 homozygotes (reference group), respectively, and APOE ε2/ε3 carriers were believed to have about half the risk of APOE ε3 homozygotes 5,7 .”
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub2 · Cited by 193
Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition
Rodriguez, G. A., Tai, L. M., LaDu, M. J., & Rebeck, G. W. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-111 · Cited by 193
“Levels of Aβ found in the AD brain are strongly affected by APOE genotype [20-22], contributing to its role as a major genetic risk factor for AD [23-25].”
BackgroundIturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Evans, A. C., & Initiative, A. T. A. D. N. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003956 · Cited by 175
“This result is in line with previous reports associating APOE e4 genotype with an earlier age at disease onset and a faster AD pathological progression [58], [59].”
ResultChornenkyy, Y., Wang, W., Wei, A., & Nelson, P. T. (2019) · Brain Pathology · doi:10.1111/bpa.12655 · Cited by 184
Sleep‐Disordered Breathing and Cognition in Older Women
Spira, A. P., Blackwell, T., Stone, K. L., Redline, S., Cauley, J. A., Ancoli‐Israel, S., & Yaffe, K. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01506.x · Cited by 185
Ramanan, V. K., & Saykin, A. J. (2013) · Europe PMC (PubMed Central) · Cited by 259
Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Yamada, K., & Nabeshima, T. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00081-4 · Cited by 190
Devassy, J. G., Leng, S., Gabbs, M., Monirujjaman, M., & Aukema, H. M. (2016) · Advances in Nutrition · doi:10.3945/an.116.012187 · Cited by 183
“In the sporadic form of AD, the apolipoprotein E (ApoE) e4 allele has the strongest association with the risk of developing AD (9).”
Phytochemicals and cognitive health: Are flavonoids doing the trick?
Bakoyiannis, I., Daskalopoulou, A., Pergialiotis, V., & Perrea, D. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.086 · Cited by 185
Therapeutic strategies for Alzheimer's disease
Wolfe, M. S. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd938 · Cited by 190
“Individuals who have one or two copies of APOE4 are at higher risk for AD, whereas carriers of the APOE2 allele have a lower risk compared with the general populatio”
BackgroundGenetics and intelligence: What's new?
Plomin, R., & Petrill, S. A. (1997) · Intelligence · doi:10.1016/s0160-2896(97)90013-1 · Cited by 193
Kim, W. S., Rahmanto, A. S., Kamili, A., Rye, K.-A., Guillemin, G. J., Gelissen, I. C., Jessup, W., Hill, A. F., & Garner, B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607831200 · Cited by 191
APOE genotype and cognition in healthy individuals at risk of Alzheimer's disease: A review
O'Donoghue, M. C., Murphy, S. E., Zamboni, G., Nobre, A. C., & Mackay, C. E. (2018) · Cortex · doi:10.1016/j.cortex.2018.03.025 · Cited by 177
Targeting mitophagy in neurodegenerative diseases
Antico, O., Thompson, P. W., Hertz, N. T., Muqit, M. M. K., & Parton, L. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01105-0 · Cited by 160
“200), a strong common genetic risk factor for both AD and dementia with Lewy bodies 201,202 .”
Amyloidosis and Alzheimer’s disease
Ghiso, J., & Frangione, B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00149-7 · Cited by 158
Androgens Protect against Apolipoprotein E4-Induced Cognitive Deficits
Raber, J., Bongers, G., LeFevour, A., Buttini, M., & Mucke, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-12-05204.2002 · Cited by 189
“Compared with apoE2 and apoE3, apoE4 increases the risk of AD and, possibly, also of age-related cognitive decline in general ( Corder et al., 1993, 1995; Roses, 1996; Farrer et al., 1997; Yaffe et al., 2000).”
BackgroundEvans, D. A. (1997) · JAMA · doi:10.1001/jama.277.10.822 · Cited by 176
Alzheimer's Disease, Apolipoprotein E4, and Gender
Payami, H. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510410028015 · Cited by 190
Holthoff, V. A., Beuthien-Baumann, B., Kalbe, E., Lüdecke, S., Lenz, O., Zündorf, G., Spirling, S., Schierz, K., Winiecki, P., Sorbi, S., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.035 · Cited by 190
Boosting power for clinical trials using classifiers based on multiple biomarkers
Kohannim, O., Hua, X., Hibar, D. P., Lee, S., Chou, Y.-Y., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.022 · Cited by 190
“We also considered ApoE genotype (coded as 0, 1 or 2 for the number of E4 alleles), age, sex and BMI, as each can influence AD risk (Corder et al., 1993, Lindsay et al., 2002, Azad et al., 2007, Buchman et al., 2005).”
Cummings, J. L., Zhong, K., Kinney, J. W., Heaney, C., Moll-Tudla, J., Joshi, A., Pontecorvo, M., Devous, M., Tang, A., & Bena, J. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0173-2 · Cited by 190
“The apolipoprotein E ε4 (ApoE4) allele is among the most potent risk factors for AD, increasing the risk of developing the disease and decreasing its age of onset [7].”
BackgroundDyslipidemia and the Risk of Alzheimer’s Disease
Reitz, C. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0307-3 · Cited by 190
“The risks of AD are three and eight times greater in individuals with one or two copies of the ε4 gene, respectively, compared with people homozygous for ε3 [38].”
BackgroundColocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment
van Bergen, J. M. G., Li, X., Hua, J., Schreiner, S. J., Steininger, S. C., Quevenco, F. C., Wyss, M., Gietl, A. F., Treyer, V., Leh, S. E., et al. (2016) · Scientific Reports · doi:10.1038/srep35514 · Cited by 180
“Regions that show significant increased iron associated coupling (T(1,7) above 10.”
BackgroundThe neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease
Beffert, U. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00008-3 · Cited by 189
Greenwood, P. M., Lambert, C., Sunderland, T., & Parasuraman, R. (2005) · Neuropsychology · doi:10.1037/0894-4105.19.2.199 · Cited by 180
“In either view, cognitive consequences would be related to ɛ4 gene dose, much as risk of AD is related to gene dose (Corder et al., 1993).”
BackgroundResultInfluentialHajjar, I., Schumpert, J., Hirth, V., Wieland, D., & Eleazer, G. P. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.7.m414 · Cited by 189
Ji, Y., Gong, Y., Gan, W., Beach, T., Holtzman, D. M., & Wisniewski, T. (2003) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.007 · Cited by 189
“The association of allele four of apoE (apoE4) as a genetic risk factor for AD has been well established, with patients expressing the E4 allele having an earlier age at onset and having a greater amyloid burden (Corder et al., 1993; Sanan et al., 1994; Wisniewski and Frangione, 1992).”
BackgroundApoE Lipidation as a therapeutic target in Alzheimer’s disease
Lanfranco, M. F., Ng, C. A., & Rebeck, G. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176336 · Cited by 189
Microglia as a Potential Bridge between the Amyloid β‐Peptide and Tau
KITAZAWA, M., YAMASAKI, T. R., & LAFERLA, F. M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.006 · Cited by 176
Extracellular Chaperones and Proteostasis
Wyatt, A. R., Yerbury, J. J., Ecroyd, H., & Wilson, M. R. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-072711-163904 · Cited by 183
Zhang, N., Gordon, M. L., & Goldberg, T. E. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.023 · Cited by 182
“It was also found that the reduced CBF correlated with evidence of cerebrovascular disease on structural MRI in the elderly, such as the volume of white matter hyperintensities (Crane et al., 2015) and cortical microbleeds (Gregg et al.”
Genomic variants, genes, and pathways of Alzheimer's disease: An overview
Naj, A. C., Schellenberg, G. D., & for the Alzheimer's Disease Genetics Consortium (ADGC) (2017) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32499 · Cited by 179
“The APOE e2/e3/e4 polymorphisms also appear to have a dosage effect on AAO: the estimated mean AAO for subsets consisting of individuals carrying no e4 allele, one e4 allele, and two e4 alleles, are 84.3, 75.5, and 68.8 years, respectively [Corder et al., 1993].”
BackgroundInfluentialGenetic correlations between Alzheimer’s disease and gut microbiome genera
Cammann, D., Lu, Y., Cummings, M. J., Zhang, M. L., Cue, J. M., Do, J., Ebersole, J., Chen, X., Oh, E. C., Cummings, J. L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-31730-5 · Cited by 163
Lynch, J. R., Morgan, D., Mance, J., Matthew, W. D., & Laskowitz, D. T. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00459-8 · Cited by 187
Arendt, T. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.09.007 · Cited by 188
Oxysterols, cholesterol homeostasis, and Alzheimer disease
Vaya, J., & Schipper, H. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04689.x · Cited by 183
PET amyloid-beta imaging in preclinical Alzheimer's disease
Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 174
HDL and cognition in neurodegenerative disorders
Hottman, D. A., Chernick, D., Cheng, S., Wang, Z., & Li, L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.015 · Cited by 182
Genetic and host factors for dementia in Down's syndrome
Schupf, N. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.405 · Cited by 188
Hudry, E., Dashkoff, J., Roe, A. D., Takeda, S., Koffie, R. M., Hashimoto, T., Scheel, M., Spires-Jones, T., Arbel-Ornath, M., Betensky, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007000 · Cited by 187
Anderton, B. H. (2002) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00426-2 · Cited by 187
Gillespie, A. K., Jones, E. A., Lin, Y.-H., Karlsson, M. P., Kay, K., Yoon, S. Y., Tong, L. M., Nova, P., Carr, J. S., Frank, L. M., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.009 · Cited by 187
“The main genetic risk factor for AD is apolipoprotein (apo) E4 (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993), one of three isoforms of the apoE protein in humans.”
BackgroundJack, C. R., Petersen, R. C., Xu, Y. C., O'Brien, P. C., Waring, S. C., Tangalos, E. G., Smith, G. E., Ivnik, R. J., Thibodeau, S. N., & Kokmen, E. (1998) · Annals of Neurology · doi:10.1002/ana.410430307 · Cited by 187
“The ∈4 allele of the apolipoprotein E (APOE) gene confers an increased risk of developing AD and also lowers the mean age of onset in a dose dependent fashion while the ∈2 allele confers a protective effect [1–9].”
BackgroundA new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease
Lambert, J. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.3.533 · Cited by 184
Sequence Diversity and Large-Scale Typing of SNPs in the Human Apolipoprotein E Gene
Nickerson, D. A., Taylor, S. L., Fullerton, S. M., Weiss, K. M., Clark, A. G., Stengård, J. H., Salomaa, V., Boerwinkle, E., & Sing, C. F. (2000) · Genome Research · doi:10.1101/gr.146900 · Cited by 184
“APOE is one of the most intensively investigated of all human loci, in large part because of its role in lipid transport and metabolism, as well as its involvement in modulating cell growth and differentiation, tissue repair, and immunoregulation (Davignon et al. 1999; Mahley and Huang 1999).”
BackgroundA genome-wide association study implicates the APOE locus in nonpathological cognitive ageing
Davies, G., Harris, S. E., Reynolds, C. A., Payton, A., Knight, H. M., Liewald, D. C., Lopez, L. M., Luciano, M., Gow, A. J., Corley, J., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2012.159 · Cited by 176
Self-citationRaha, A. A., Vaishnav, R. A., Friedland, R. P., Bomford, A., & Raha-Chowdhury, R. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-55 · Cited by 177
“Another key protein involved in AD is apolipoprotein E (ApoE), a major genetic risk factor with 60-80% of affected individuals having at least one ApoE4 allele [12-15].”
BackgroundTang, M. X., Maestre, G. E., Tsai, W., Liu, X., Feng, L., Chung, W.-Y., Chun, M. R., Schofield, P. R., Stern, Y., Tycko, B., et al. (1996) · PubMed · doi:10.7916/d80v9r96 · Cited by 185
Schulz, U. G. R., Flossmann, E., & Rothwell, P. M. (2004) · Stroke · doi:10.1161/01.str.0000121646.23955.0f · Cited by 184
Naj, A. C., Jun, G., Reitz, C., Kunkle, B. W., Perry, W., Park, Y. S., Beecham, G. W., Rajbhandary, R. A., Hamilton-Nelson, K. L., Wang, L.-S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1491 · Cited by 185
Self-citationBu, G., Maksymovitch, E. A., Nerbonne, J. M., & Schwartz, A. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32340-2 · Cited by 185
Gene-environment interactions in mental disorders.
Tsuang, M. T., Bar, J. L., Stone, W. S., & Faraone, S. V. (2004) · Europe PMC (PubMed Central) · Cited by 249
Peptidyl-prolyl cis–trans isomerase Pin1 in ageing, cancer and Alzheimer disease
Lee, T. H., Pastorino, L., & Lu, K. P. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001906 · Cited by 181
Cognitive predictors of incident Alzheimer's disease: A prospective longitudinal study.
Small, B. J., Herlitz, A., Fratiglioni, L., & Almkvist, O. (1997) · Neuropsychology · doi:10.1037//0894-4105.11.3.413 · Cited by 182
Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease
Perry, G., Castellani, R. J., Hirai, K., & Smith, M. A. (1998) · Journal of Alzheimer's Disease · doi:10.3233/jad-1998-1103 · Cited by 185
“Several independent hypotheses have been proposed to link the pathological lesions and neuronal cytopathology with, among others, apolipoprotein E genotype (17,84), hyperphosphorylation of cytoskeletal proteins (119), and amyloid-β metabolism (92).”
BackgroundThe Genetics of Alzheimer Disease: Current Status and Future Prospects
Blacker, D., & Tanzi, R. E. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.294 · Cited by 182
Dementia in Africa: current evidence, knowledge gaps, and future directions
Akinyemi, R. O., Yaria, J., Ojagbemi, A., Guerchet, M., Okubadejo, N., Njamnshi, A. K., Sarfo, F. S., Akpalu, A., Ogbole, G., Ayantayo, T., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12432 · Cited by 184
Self-citationWhalley, L. J., Deary, I. J., Starr, J. M., Wahle, K. W., Rance, K. A., Bourne, V. J., & Fox, H. C. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.2.449 · Cited by 180
Mild Cognitive Impairment in Geriatrics
Tangalos, E. G., & Petersen, R. C. (2018) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2018.06.005 · Cited by 170
A global view of the genetic basis of Alzheimer disease
Reitz, C., Pericak-Vance, M. A., Foroud, T., & Mayeux, R. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00789-z · Cited by 157
Self-citationNeuroimaging Findings in Twins Discordant for Alzheimer’s Disease
Pedersen, N. L., Miller, B. L., Loebach Wetherell, J., Vallø, J., Toga, A. W., Knutson, N., Mehringer, C. M., Small, G. W., & Gatz, M. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017097 · Cited by 180
Self-citationBeher, D., Hesse, L., Masters, C. L., & Multhaup, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.3.1613 · Cited by 170
Suri, S., Heise, V., Trachtenberg, A. J., & Mackay, C. E. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.010 · Cited by 183
“In the last few decades several genes that increase susceptibility to AD have been identified, of which the apolipoprotein (APOE) !4 allele stands out as the best-established risk factor for sporadic late-onset AD (Corder et al., 1993; Farrer et al., 1997).”
BackgroundSuccessful therapies for Alzheimer’s disease: why so many in animal models and none in humans?
Franco, R., & Cedazo-Minguez, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00146 · Cited by 183
Buttini, M., Yu, G.-Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M., & Mucke, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10539.2002 · Cited by 183
“Because synaptic deficits correlate well with the development of cognitive deficits in AD (DeKosky and Scheff, 1990; Terry et al., 1991; Langlais et al., 1993; Samuel et al., 1997; Sze et al., 1997; Brown et al., 1998), the differential effects of apoE3 and apoE4 identified here might relate closely to the effects of…”
BackgroundInfluentialApolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
Najm, R., Jones, E. A., & Huang, Y. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0324-6 · Cited by 183
Bacterial Infection and Alzheimer's Disease: A Meta-Analysis
Maheshwari, P., & Eslick, G. D. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140621 · Cited by 183
Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease
Escott-Price, V., Shoai, M., Pither, R., Williams, J., & Hardy, J. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.018 · Cited by 183
“Along with the APOE polymorphism (Corder et al., 1993), 20 common susceptibility loci ( ABCA7 , BIN1 , CD33 , CLU , CR1 , CD2AP , EPHA1 , MS4A4 , PICALM , HLA-DRB5/DRB1 , SORL1 , PTK2B , SLC24A4/RIN3 , ZCWPW1 , SELF1 , NME8 , FERMT2 , CASS4 , INPP5D , MEF2C , CD33 ) have been identi fi ed to be…”
Grainger, D. J., Reckless, J., & McKilligin, E. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6366 · Cited by 183
Hultman, K., Strickland, S., & Norris, E. H. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.76 · Cited by 183
Increased Risk of Late Posttraumatic Seizures Associated With Inheritance of APOE ϵ4 Allele
Diaz-Arrastia, R., Gong, Y., Fair, S., Scott, K. D., Garcia, M. C., Carlile, M. C., Agostini, M. A., & Van Ness, P. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.6.818 · Cited by 185
Dementia of the Alzheimer Type
Jalbert, J. J., Daiello, L. A., & Lapane, K. L. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn008 · Cited by 174
“Earlier age at onset is observed in a dose-dependent fashion (the average age at onset for persons with genotype e4/e4, only one e4 allele, and no e4 allele is 68 years, 76 years, and 84 years, respectively) (101).”
BackgroundA mitochondrial DNA clone is associated with increased risk for Alzheimer disease.
Hutchin, T., & Cortopassi, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6892 · Cited by 186
Licastro, F., Grimaldi, L. M. E., Bonafè, M., Martina, C., Olivieri, F., Cavallone, L., Giovanietti, S., Masliah, E., & Franceschi, C. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00013-7 · Cited by 182
“one, the apolipoprotein E (APOE) gene, has been associated with both sporadic and familial AD [9,31].”
BackgroundPathophysiology of Delirium in the Intensive Care Unit
Gunther, M. L., Morandi, A., & Ely, E. W. (2008) · Critical Care Clinics · doi:10.1016/j.ccc.2007.10.002 · Cited by 176
Ortiz-Virumbrales, M., Moreno, C. L., Kruglikov, I., Marazuela, P., Sproul, A., Jacob, S., Zimmer, M., Paull, D., Zhang, B., Schadt, E. E., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0475-z · Cited by 171
“The presence of this allelic variant, the most common and well characterized risk factor polymorphism for LOAD [16], may modulate the age of onset and severity of the phenotype [49].”
Apolipoprotein E and Alzheimer's disease
Troutwine, B. R., Hamid, L., Lysaker, C. R., Strope, T. A., & Wilkins, H. M. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.002 · Cited by 156
Apolipoprotein E-ε4 protects against severe liver disease caused by hepatitis C virus
Wozniak, M. A., Itzhaki, R. F., Faragher, B. E., James, M. W., Ryder, S. D., & Irving, W. L. (2002) · Hepatology · doi:10.1053/jhep.2002.34745 · Cited by 181
“Men:women 51:25 25:10 Mean age at biopsy procedure (y) 38 (21-80) 49 (34-72)* Mean duration of infection (y) 18 (4-41) 18 (6-38) Mean weekly alcohol intake (U) 9 (0-65) 7 (0-62)† Risk factor Intravenous drug user 52 19 Blood product transfusion 6 9 Other known 4 1 Unknown 14 6”
Effects of in vivo conditions on amyloid aggregation
Owen, M. C., Gnutt, D., Gao, M., Wärmländer, S. K. T. S., Jarvet, J., Gräslund, A., Winter, R., Ebbinghaus, S., & Strodel, B. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00034d · Cited by 182
Benussi, A., Cantoni, V., Grassi, M., Brechet, L., Michel, C. M., Datta, A., Thomas, C., Gazzina, S., Cotelli, M. S., Bianchi, M., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26411 · Cited by 163
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Toledo, J. B., Xie, S. X., Trojanowski, J. Q., & Shaw, L. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1151-4 · Cited by 180
“Our results favor the hypothesis that harboring at least one APOE ε 4 allele advances in time the onset of A β accumulation in line with the effect observed on age of clinical onset of AD [6].”
Aβ Toxicity in Alzheimer's Disease
Cavallucci, V., D’Amelio, M., & Cecconi, F. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8251-3 · Cited by 177
“zygous individuals [22, 23].”
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.